Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$17.46 USD

17.46
4,274,858

-0.21 (-1.19%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $17.41 -0.05 (-0.29%) 5:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 15% (39 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents

by Zacks Equity Research

The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.

    AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study

    by Zacks Equity Research

    AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.

      BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates

      by Zacks Equity Research

      BioDelivery Sciences' (BDSI) reports narrower-than-expected loss in Q1. Sales marginally beat the consensus mark.

        Ekta Bagri headshot

        Mylan (MYL) Q1 Earnings Lag on Weak North America Sales

        by Ekta Bagri

        Mylan's first-quarter results were dismal with both earnings and sales missing expectations as challenges in North America persist.

          Momenta (MNTA) Incurs Wider Y/Y Loss, Glatopa Sales Decline

          by Zacks Equity Research

          Momenta reported a wider year-over-year loss in the first quarter. Sales of Glatopa declined due to competition from Mylan.

            Mylan (MYL) to Report Q1 Earnings: What's in the Offing?

            by Zacks Equity Research

            Investors are exepcted to focus on the performance of EpiPen, newly launched drugs and the progress of the company's biosimilars pipeline when Mylan (MYL) reports results for the Q1.

              Teva (TEVA) Stock Dips Despite Q1 Earnings & Sales Beat

              by Zacks Equity Research

              Teva's (TEVA) shares dip despite first-quarter earnings and sales beat. The company raises its 2018 sales and earnings outlook.

                Kinjel Shah headshot

                Teva (TEVA) Up on Q1 Earnings & Sales Beat, Rise in Guidance

                by Kinjel Shah

                Teva's (TEVA) first-quarter earnings and sales beat expectations. The company raises its 2018 sales and earnings outlook. Stock up in pre-market trading.

                  Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

                  by Zacks Equity Research

                  Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone is likely to hurt sales of the Specialty segment.

                    Novartis (NVS) Reports Encouraging Data on MS Candidate

                    by Zacks Equity Research

                    Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

                      Amgen's Aimovig Reduces Episodic Migraine in 30% Patients

                      by Zacks Equity Research

                      Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.

                        Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug

                        by Zacks Equity Research

                        Mylan (MYL) has inked a deal with Israel based Mapi Pharma to acquire its multiple sclerosis candidate.

                          AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome

                          by Zacks Equity Research

                          AbbVie's (ABBV) key lung cancer candidate, Rova-T falls short in a phase II study. AbbVie will not seek accelerated approval of Rova-T in the third-line setting

                            BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y

                            by Zacks Equity Research

                            BioDelivery (BDSI) reports wider-than-expected loss in Q4. However, revenues surpass estimates and increase substantially year over year.

                              Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

                              by Zacks Equity Research

                              Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

                                Pharma Stocks Weighed Down by Competition, Generic Pressure

                                by Zacks Equity Research

                                Although pharma and biotech sectors rebounded in 2017 and started 2018 on an optimistic note, drug companies may find it a bit difficult to justify their high prices.

                                  Can New Approvals Help Mylan Stock Turn Around in 2018?

                                  by Zacks Equity Research

                                  Mylan (MYL) faced challenging conditions in 2017 but 2018 is expected to be better driven by new product launches.

                                    Pharmaceutical Industry Outlook - March 2018

                                    by Zacks Equity Research

                                    The year 2017 was rewarding for pharma and biotech stocks, with the sector witnessing some positive developments that led to a much-awaited recovery.

                                      Mylan (MYL) Q4 Earnings Surpass Estimates, Revenues Miss

                                      by Zacks Equity Research

                                      Mylan???s (MYL) mixed Q4 results show earnings beat but revenues miss on pricing pressure and weak EpiPen sales.

                                        Will Mylan (MYL) Disappoint Investors This Earnings Season?

                                        by Zacks Equity Research

                                        During the Q4 earnings call, investors are expected to remain focused on the performance of Mylan's (MYL) EpiPen, newly launched drugs and the progress of the biosimilars pipeline.

                                          United Therapeutics (UTHR) Q4 Earnings Decline on High Costs

                                          by Zacks Equity Research

                                          United Therapeutics' (UTHR) earnings per share decline in Q4 due to higher operating costs. Shares sink almost 10%.

                                            Momenta's (MNTA) Earnings & Revenues Surpass Estimates in Q4

                                            by Zacks Equity Research

                                            Momenta (MNTA) delivers better-than-expected fourth-quarter results on the back of an upfront payment from CSL.

                                              Teva's Problems Continue to Mount With No Relief in Sight

                                              by Zacks Equity Research

                                              Teva (TEVA) faces significant challenges including rapid erosion in sales of Copaxone and pricing erosion in the U.S. generics business.

                                                J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)

                                                by Zacks Equity Research

                                                J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

                                                  Ryan McQueeney headshot

                                                  Here's Why Teva Pharma Stock Is Soaring Today

                                                  by Ryan McQueeney

                                                  Shares of Teva Pharmaceuticals (TEVA) gained more than 10% in early morning trading Thursday after news emerged Wednesday that Warren Buffett's Berkshire Hathaway (BRK.B) took a massive stake in the struggling drugmaker during the fourth quarter.